Asie · Bourse & Finance · Vietnam Investment Review

CSL secures lixudebart licensing deal with Alentis for 355 million dollars

Publié par Vietnam Investment Review · Vietnam il y a 10 h

Biopharmaceutical firm CSL paid 355 million US dollars upfront to Alentis to commercialise lixudebart, pledging up to 1.2 billion US dollars in milestone payments for rare disease…

Lire l'article complet sur Vietnam Investment Review Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (vir.com.vn)

CSL secures lixudebart licensing deal with Alentis for 355 million dollars

À lire aussi

DBS CEO Tan Su Shan, environmental advocate Kong Man Jing win at Her World’s annual awards

Nifty Outlook for October 7: Bulls regain control, 23,000 resistance in focus ahead of RBI policy

Sebi vs Jane Street: 'Dilatory tactic; ulta chor kotwal ko daante' - What the markets regulator's lawyer said in hearing

Max Estates bookings surge to Rs 2,100 crore

รัฐบาลดึง ‘เนเน่’ แขกพิเศษ นายกฯ โชว์พลังเสียงต้อนรับ 400 ผู้นำการเงินโลก

Singapore security firm V-Key takes stake in CloudsineAI

CSL secures lixudebart licensing deal with Alentis for 355 million dollars

Partager

À lire aussi

DBS CEO Tan Su Shan, environmental advocate Kong Man Jing win at Her World’s annual awards

Nifty Outlook for October 7: Bulls regain control, 23,000 resistance in focus ahead of RBI policy

Sebi vs Jane Street: 'Dilatory tactic; ulta chor kotwal ko daante' - What the markets regulator's lawyer said in hearing

Max Estates bookings surge to Rs 2,100 crore

รัฐบาลดึง ‘เนเน่’ แขกพิเศษ นายกฯ โชว์พลังเสียงต้อนรับ 400 ผู้นำการเงินโลก

Singapore security firm V-Key takes stake in CloudsineAI